These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 25122785)

  • 21. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections.
    Nunnari G; Otero M; Dornadula G; Vanella M; Zhang H; Frank I; Pomerantz RJ
    AIDS; 2002 Jan; 16(1):39-45. PubMed ID: 11741161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV type 2 proviral load measured by quantitative polymerase chain reaction correlates with CD4+ lymphopenia in HIV type 2-infected individuals.
    Berry N; Ariyoshi K; Jobe O; Ngum PT; Corrah T; Wilkins A; Whittle H; Tedder R
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):1031-7. PubMed ID: 7811534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a droplet digital polymerase chain reaction assay for the sensitive detection of total and integrated HIV-1 DNA.
    Yuan L; Liu Z; Zhang X; Wei F; Guo S; Guo N; Liu L; Ma Z; Ji Y; Wang R; Lu X; Li Z; Xia W; Wu H; Zhang T; Su B
    Chin Med J (Engl); 2024 Mar; 137(6):729-736. PubMed ID: 38433332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.
    Besson GJ; Lalama CM; Bosch RJ; Gandhi RT; Bedison MA; Aga E; Riddler SA; McMahon DK; Hong F; Mellors JW
    Clin Infect Dis; 2014 Nov; 59(9):1312-21. PubMed ID: 25073894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of southern African human immunodeficiency virus type 1 subtypes by polymerase chain reaction: evaluation of different primer pairs and conditions.
    Engelbrecht S; van Rensburg EJ
    J Virol Methods; 1995 Nov; 55(3):391-400. PubMed ID: 8609204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of HIV DNA Using Droplet Digital PCR Techniques.
    Anderson EM; Maldarelli F
    Curr Protoc Microbiol; 2018 Nov; 51(1):e62. PubMed ID: 30253074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
    J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens.
    Kiselinova M; Geretti AM; Malatinkova E; Vervisch K; Beloukas A; Messiaen P; Bonczkowski P; Trypsteen W; Callens S; Verhofstede C; De Spiegelaere W; Vandekerckhove L
    J Antimicrob Chemother; 2015 Dec; 70(12):3311-6. PubMed ID: 26324076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children.
    Ananworanich J; Puthanakit T; Suntarattiwong P; Chokephaibulkit K; Kerr SJ; Fromentin R; Bakeman W; Intasan J; Mahanontharit A; Sirivichayakul S; Chomont N;
    AIDS; 2014 Apr; 28(7):1015-20. PubMed ID: 24384692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy.
    Massanella M; Bakeman W; Sithinamsuwan P; Fletcher JLK; Chomchey N; Tipsuk S; Chalermchai T; Routy JP; Ananworanich J; Valcour VG; Chomont N
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31597764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
    Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
    Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. After 18 months of antiretroviral therapy, total HIV DNA decreases more pronouncedly in patients infected by CRF01_AE than in those infected by subtype B and CRF07_BC.
    Lu Z; Jiao Y; Li J; Lan G; Lu C; Li X; Tang Z; Wang N
    Microbiol Immunol; 2018 Apr; 62(4):248-254. PubMed ID: 29377267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers.
    Hatano H; Somsouk M; Sinclair E; Harvill K; Gilman L; Cohen M; Hoh R; Hunt PW; Martin JN; Wong JK; Deeks SG; Yukl SA
    AIDS; 2013 Sep; 27(14):2255-60. PubMed ID: 24157906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis and generation of a robust HIV-1 DNA quantification assay.
    Thomas J; Ruggiero A; Procopio FA; Pantaleo G; Paxton WA; Pollakis G
    J Virol Methods; 2019 Jan; 263():24-31. PubMed ID: 30326210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of total HIV-1 DNA in buffy coat cells, feasibility and potential added value for clinical follow-up of HIV-1 infected patients on ART.
    Mortier V; Demecheleer E; Staelens D; Schauvliege M; Dauwe K; Dinakis S; Hebberecht L; Vancoillie L; Verhofstede C
    J Clin Virol; 2018 Sep; 106():58-63. PubMed ID: 30077957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
    Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
    J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent high levels of immune activation and their correlation with the HIV-1 proviral DNA and 2-LTR circles loads, in a cohort of Mexican individuals following long-term and fully suppressive treatment.
    Orta-Resendiz A; Viveros-Rogel M; Fuentes-Romero LL; Vergara-Mendoza M; Romero-Rodriguez DP; Muñoz-Lopez M; Zancatl-Diaz ML; Vidal-Laurencio EY; Rodriguez-Diaz RA; Soto-Ramirez LE
    Int J Infect Dis; 2020 Nov; 100():184-192. PubMed ID: 32829045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings.
    Steegen K; Luchters S; De Cabooter N; Reynaerts J; Mandaliya K; Plum J; Jaoko W; Verhofstede C; Temmerman M
    J Virol Methods; 2007 Dec; 146(1-2):178-87. PubMed ID: 17686534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4
    Song CB; Zhang LL; Wu X; Fu YJ; Jiang YJ; Shang H; Zhang ZN
    J Transl Med; 2020 Feb; 18(1):95. PubMed ID: 32093678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.